Compare ABG & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABG | ALKS |
|---|---|---|
| Founded | 1996 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.8B |
| IPO Year | N/A | 1991 |
| Metric | ABG | ALKS |
|---|---|---|
| Price | $232.48 | $29.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $264.71 | $42.85 |
| AVG Volume (30 Days) | 170.2K | ★ 2.9M |
| Earning Date | 10-28-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.57 | 2.44 |
| EPS | ★ 28.52 | 2.02 |
| Revenue | ★ $17,827,000,000.00 | $1,521,338,000.00 |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $8.69 | $24.60 |
| P/E Ratio | ★ $8.15 | $14.70 |
| Revenue Growth | ★ 8.07 | 1.08 |
| 52 Week Low | $201.68 | $25.17 |
| 52 Week High | $312.56 | $36.45 |
| Indicator | ABG | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 46.66 |
| Support Level | $210.67 | $27.90 |
| Resistance Level | $241.97 | $31.74 |
| Average True Range (ATR) | 7.69 | 1.36 |
| MACD | 2.10 | -0.15 |
| Stochastic Oscillator | 72.14 | 27.71 |
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 152 new-vehicle stores and 37 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 14 states (mostly Texas, the West, the Mid-Atlantic, and the Southeast). Asbury store brands include McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated $17.2 billion of revenue in 2024 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.